TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39666578

Group type: EXPERIMENTAL
Intervention: Hypertonic saline nasal irrigation and gargling (HSNIG) with a 2.6% hypertonic saline solution.
Number of subjects: 576

Group type: COMPARATOR
Intervention: Control group performing ablution for Muslim prayers (wudu) with tap water.
Number of subjects: 576
Study: 39666696

Group type: EXPERIMENTAL
Intervention: Hypopressive exercises
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Conventional exercises
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both exercise programs
Number of subjects: 28
Study: 39666930

Group type: EXPERIMENTAL
Intervention: Genomic sequencing (GS)
Number of subjects: 276
Study: 39666929

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 9
Study: 39666948

Group type: EXPERIMENTAL
Intervention: Memo 4D intervention
Number of subjects: 166
Study: 39666984

Group type: EXPERIMENTAL
Intervention: Highly effective modulator therapy
Number of subjects: 0
Study: 39666985

Group type: EXPERIMENTAL
Intervention: aD1
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: antiphosphatidylserine-prothrombin IgG
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: lupus anticoagulant
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: antiphosphatidylserine-prothrombin IgM
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: anticardiolipin IgG
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: lupus anticoagulant positivity with aD1 and antiphosphatidylserine-prothrombin IgG
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Combined use of aD1 and antiphosphatidylserine-prothrombin IgG
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Overall adverse pregnancy outcomes
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: ROC analysis for aD1
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: ROC analysis for antiphosphatidylserine-prothrombin IgG
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: ROC analysis for antiphosphatidylserine-prothrombin IgM
Number of subjects: 265
Study: 39667036

Group type: EXPERIMENTAL
Intervention: Carbapenemase-producing Enterobacter spp. infections
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Older age at enrollment
Number of subjects: 136
Study: 39667380

Group type: EXPERIMENTAL
Intervention: Hypovolaemic phlebotomy
Number of subjects: 486

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 486
Study: 39667379

Group type: EXPERIMENTAL
Intervention: PGT121.414.LS 3 mg/kg intravenous
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PGT121.414.LS 10 mg/kg intravenous
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PGT121.414.LS 30 mg/kg intravenous
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PGT121.414.LS 5 mg/kg subcutaneous
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PGT121.414.LS 20 mg/kg intravenous plus VRC07-523LS 20 mg/kg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PGT121.414.LS 5 mg/kg subcutaneous plus VRC07-523LS 5 mg/kg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PGT121.414.LS (all doses)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PGT121.414.LS (subcutaneous)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PGT121.414.LS and VRC07-523LS (higher-dose and dual combination intravenous)
Number of subjects: 33
Study: 39667975

Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (25-50 IU/kg) at least twice weekly
Number of subjects: 82
Study: 39668137

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Nonplatinum chemotherapy (physician's choice of pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan)
Number of subjects: 266
Study: 39668350

Group type: EXPERIMENTAL
Intervention: SC-VR intervention (n=64)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Wait-list group (n=64)
Number of subjects: 128
Study: 39668364

Group type: EXPERIMENTAL
Intervention: Neuroathletic training exercises
Number of subjects: 19

Group type: COMPARATOR
Intervention: Traditional movement therapy
Number of subjects: 19
Study: 39668486

Group type: EXPERIMENTAL
Intervention: Delayed 68Ga-FAPI-04 PET/CT
Number of subjects: 69
Study: 39668544

Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI) system
Number of subjects: 131

Group type: COMPARATOR
Intervention: Inexperienced physicians
Number of subjects: 131

Group type: COMPARATOR
Intervention: Experienced physicians
Number of subjects: 131
Study: 39668580

Group type: EXPERIMENTAL
Intervention: SLC22A1 1022C>T (CT genotype)
Number of subjects: 16
Study: 39669005

Group type: EXPERIMENTAL
Intervention: Intraarticular corticosteroid injections
Number of subjects: 354

Group type: COMPARATOR
Intervention: Saline injections
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Synovitis by MRI
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Hand function by MAP-Hand questionnaire
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Synovitis by clinical examination and ultrasound
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Measures of pain, function, stiffness, and health-related quality of life
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Direct and indirect costs
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 354
Study: 39669115

Group type: EXPERIMENTAL
Intervention: Flat flexible footwear (FFF) added to exercise therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stable supportive shoes (SSS) added to exercise therapy
Number of subjects: 0
Study: 39669537

Group type: EXPERIMENTAL
Intervention: GAIN-Q4
Number of subjects: 101897
Study: 39669652

Group type: EXPERIMENTAL
Intervention: Mild autonomous cortisol secretion (MACS) group (1 mg-DST > 1.8 µg/dL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-functioning adrenal tumor group (1 mg-DST ≤ 1.8 µg/dL)
Number of subjects: 90
Study: 39670007

Group type: EXPERIMENTAL
Intervention: Imprime PGG (4 mg/kg)
Number of subjects: 33
Study: 39670171

Group type: EXPERIMENTAL
Intervention: CRPS patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: HHC
Number of subjects: 25

Group type: COMPARATOR
Intervention: Mouse model of CRPS
Number of subjects: 25
Study: 39670353

Group type: EXPERIMENTAL
Intervention: Upper lobectomy
Number of subjects: 226

Group type: COMPARATOR
Intervention: Lower lobectomy
Number of subjects: 226
Study: 39670468

Group type: EXPERIMENTAL
Intervention: Bavdegalutamide (ARV-110)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bavdegalutamide (ARV-110) in combination with abiraterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 0
Study: 39670843

Group type: EXPERIMENTAL
Intervention: Fluorine 18
Number of subjects: 0
Study: 39671024

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) intake (60 g of maltodextrin + fructose)
Number of subjects: 23
Study: 39671076

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 39671157

Group type: EXPERIMENTAL
Intervention: Metformin extended release up to 750 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle and risk factor modification (LRFM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined therapy of metformin and LRFM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39671174

Group type: EXPERIMENTAL
Intervention: Stable gp120 vaccine with GLA-SE adjuvant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transient gp120 vaccine with GLA-SE adjuvant
Number of subjects: 0
Study: 39671199

Group type: EXPERIMENTAL
Intervention: SINEMA intervention (system-integrated technology-enabled model of care)
Number of subjects: 998

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 998
Study: 39671198

Group type: EXPERIMENTAL
Intervention: Intact placental circulation for 180 seconds
Number of subjects: 209

Group type: COMPARATOR
Intervention: Umbilical cord milking followed by early cord clamping (within 20 seconds of life)
Number of subjects: 209
Study: 39671203

Group type: EXPERIMENTAL
Intervention: Mobile application-based coaching (high-tech)
Number of subjects: 4852

Group type: EXPERIMENTAL
Intervention: In-person coaching of clinicians (high-touch)
Number of subjects: 4852

Group type: COMPARATOR
Intervention: Posters placed in examination rooms (ASK)
Number of subjects: 4852
Study: 39671266

Group type: EXPERIMENTAL
Intervention: Nurse-Family Partnership (NFP)
Number of subjects: 4932

Group type: COMPARATOR
Intervention: Standard of care treatment (control)
Number of subjects: 4932
Study: 39671272

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 441
Study: 39671525

Group type: EXPERIMENTAL
Intervention: Interlaminar epidural steroid injection + dry needling
Number of subjects: 66

Group type: COMPARATOR
Intervention: Interlaminar epidural steroid injection + sham dry needling
Number of subjects: 66

Group type: COMPARATOR
Intervention: Only interlaminar epidural steroid injection
Number of subjects: 66
Study: 39671533

Group type: EXPERIMENTAL
Intervention: Nivolumab plus relatlimab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 0
Study: 39671539

Group type: EXPERIMENTAL
Intervention: CT response score (CTRS) from deep learning radiomic biomarker in RWD Test Data Set B (n = 458)
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: CTRS in Clinical Trial Data Set C (n = 54)
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: CTRS and eCTRS
Number of subjects: 1829
Study: 39671543

Group type: EXPERIMENTAL
Intervention: Nicotinamide (1,500 mg twice a day for 48 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 39671552

Group type: EXPERIMENTAL
Intervention: Angiotensin II (ANGII)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 39671573

Group type: EXPERIMENTAL
Intervention: Active iTBS intervention (intermittent theta burst stimulation), performed daily, 5 days a week, for 2 weeks.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham iTBS (control group).
Number of subjects: 56
Study: 39671575

Group type: EXPERIMENTAL
Intervention: Theory-based physical activity intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 64
Study: 39671585

Group type: EXPERIMENTAL
Intervention: Gamified Home-Based Cognitive-Nutritional (GAHOCON) training for 12 weeks (4 weeks center-based training + 8 weeks home-based training).
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group received 4 weeks of center-based training and 8 weeks of self-revision of health educational materials.
Number of subjects: 25
Study: 39671695

Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etrasimod with concomitant 5-ASA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concomitant corticosteroids (CS) only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concomitant CS + 5-ASA
Number of subjects: 0
Study: 39671752

Group type: EXPERIMENTAL
Intervention: CLR 131 with external beam radiation therapy (EBRT)
Number of subjects: 12
Study: 39671779

Group type: EXPERIMENTAL
Intervention: Early decrease of circulating tumor DNA (ctDNA) ratio after one cycle of neoadjuvant chemotherapy (NACT)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Early decrease of ctDNA ratio
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Detectable ctDNA at diagnosis (T0)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Negative ctDNA or decrease of more than 80% after one cycle of NACT (T1)
Number of subjects: 188
Study: 39672082

Group type: EXPERIMENTAL
Intervention: MCT/LCT PN
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Olive oil-based PN
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: n-3 PUFA-enriched PN
Number of subjects: 94
Study: 39672101

Group type: EXPERIMENTAL
Intervention: Self-guided e-learning program
Number of subjects: 115

Group type: COMPARATOR
Intervention: Delayed-start control condition
Number of subjects: 115
Study: 39672183

Group type: COMPARATOR
Intervention: RH5.1/Matrix-M delayed third-dose regimen
Number of subjects: 361

Group type: COMPARATOR
Intervention: RH5.1/Matrix-M monthly regimen
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M (both cohorts)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M
Number of subjects: 361
Study: 39672366

Group type: EXPERIMENTAL
Intervention: TSH ≥2.0 mU/L and TPO-Ab ≥30 U/mL (exposed)
Number of subjects: 1578

Group type: COMPARATOR
Intervention: TSH <2.0 mU/L and TPO-Ab <30 U/mL (unexposed)
Number of subjects: 1578
Study: 39672515

Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated intensity modulated proton therapy (IMPT) with 67.5 Gy to prostate/seminal vesicles and 45 Gy to pelvic lymph nodes in 25 daily fractions, all received androgen deprivation therapy.
Number of subjects: 56
Study: 39672574

Group type: EXPERIMENTAL
Intervention: Primary posterior tracheopexy (PPT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No primary posterior tracheopexy (no-PPT)
Number of subjects: 78
Study: 39672576

Group type: EXPERIMENTAL
Intervention: Knee osteotomy combined with meniscal allograft transplantation (MAT)
Number of subjects: 52
Study: 39672583

Group type: EXPERIMENTAL
Intervention: Liver steatosis
Number of subjects: 1816

Group type: EXPERIMENTAL
Intervention: Liver fibrosis
Number of subjects: 1816

Group type: EXPERIMENTAL
Intervention: Cirrhosis
Number of subjects: 1816

Group type: EXPERIMENTAL
Intervention: Risk factors for steatosis
Number of subjects: 1816

Group type: EXPERIMENTAL
Intervention: Risk factors for fibrosis
Number of subjects: 1816
Study: 39672815

Group type: EXPERIMENTAL
Intervention: Mepolizumab, reslizumab, or dupilumab
Number of subjects: 8
Study: 39672984

Group type: EXPERIMENTAL
Intervention: Medically tailored meals (MTM) with medical nutrition therapy (MNT) - home delivery of 12 medically tailored frozen meals and a fresh produce bag weekly for 3 months, plus monthly calls with a registered dietitian for 6 months.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Medically tailored meals (MTM) with medical nutrition therapy (MNT)
Number of subjects: 74
Study: 39672986

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Genomic datasets from stored biospecimens
Number of subjects: 218
Study: 39673015

Group type: EXPERIMENTAL
Intervention: Baseline PD-L1 targeted peptide PET/CT
Number of subjects: 20
Study: 39673053

Group type: EXPERIMENTAL
Intervention: Moderate/Severe OSA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mild OSA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Patients without OSA and/or ND
Number of subjects: 80
Study: 39673171

Group type: COMPARATOR
Intervention: High-dose denosumab (120 mg/month with loading doses on weeks 2 and 3) for 6 months
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moderate-dose denosumab (120 mg/3 months)
Number of subjects: 8
Study: 39673281

Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing of subjects without conventional risk factors
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: Carriers of mutations from CABP1, HLA-E, TOE1, and HPSE2
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: Extracellular matrix-associated CHST14 and fibrinogen-associated KLHL8
Number of subjects: 1950
Study: 39673298

Group type: EXPERIMENTAL
Intervention: Daily coffee consumption (>5 cups/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily coffee consumption (<1 cup/day)
Number of subjects: 0
Study: 39673311

Group type: EXPERIMENTAL
Intervention: dd-cfDNA-guided biopsy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clinician-guided biopsy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: dd-cfDNA monitoring
Number of subjects: 40
Study: 39673334

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy, 2.5 mg subcutaneous injections daily from Day 1 of ovarian stimulation until oocyte retrieval
Number of subjects: 288

Group type: COMPARATOR
Intervention: Standard ovarian stimulation without adjuvant therapy (Control)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 288
Study: 39673367

Group type: EXPERIMENTAL
Intervention: Dupilumab + OIT (n=84)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo + OIT (n=39)
Number of subjects: 148
Study: 39673396

Group type: EXPERIMENTAL
Intervention: Leniolisib
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 148
Study: 39673415

Group type: EXPERIMENTAL
Intervention: Guselkumab 400 mg intravenous infusion at Weeks 0, 4, and 8, followed by 200 mg subcutaneous injections at Week 12 and every 4 weeks through Week 48, in addition to background therapy.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo intravenous infusion at Weeks 0, 4, and 8, followed by placebo subcutaneous injections at Week 12 and every 4 weeks through Week 48, in addition to background therapy.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Guselkumab + background therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo + background therapy
Number of subjects: 33
Study: 39673443

Group type: EXPERIMENTAL
Intervention: Immediate mNC-FET
Number of subjects: 528

Group type: COMPARATOR
Intervention: Postponed mNC-FET
Number of subjects: 528
Study: 39673447

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC) via endoscopic injection
Number of subjects: 9
Study: 39673452

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg (≥ 60 kg) or 200 mg (≥ 20 to < 60 kg) subcutaneously every 2 weeks for 24 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 24
Study: 39673591

Group type: EXPERIMENTAL
Intervention: Oral triapine (100 mg, five days a week for five weeks) with weekly IV cisplatin chemoradiation
Number of subjects: 21
Study: 39673658

Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (DMF)
Number of subjects: 5124
Study: 39673713

Group type: EXPERIMENTAL
Intervention: Freethiadine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Entecavir
Number of subjects: 40
Study: 39673746

Group type: EXPERIMENTAL
Intervention: Oral vancomycin (OV) 125mg QID for 4 weeks
Number of subjects: 15
Study: 39673779

Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 142

Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 142
Study: 39673810

Group type: EXPERIMENTAL
Intervention: Niraparib at individualized starting dose (ISD) 200 mg/day
Number of subjects: 139
Study: 39673820

Group type: EXPERIMENTAL
Intervention: Pravastatin group
Number of subjects: 792

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Patients above sBP 154, 159 and 160 mmHg or dBP 101 mmHg at baseline
Number of subjects: 792
Study: 39673909

Group type: EXPERIMENTAL
Intervention: DA-led reinstruction and remotivation of nursing staff by dental assistants (DAs) over 13 months
Number of subjects: 358

Group type: COMPARATOR
Intervention: Standard of care (similar interventions prescribed without reinstruction and remotivation)
Number of subjects: 358
Study: 39674007

Group type: EXPERIMENTAL
Intervention: Extreme Gradient Boosting (XGBoost) algorithm
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Prolonged hospitalization and intensive care unit stay
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Artificial intelligence in healthcare
Number of subjects: 289
Study: 39674178

Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Number of subjects: 0
Study: 39674369

Group type: EXPERIMENTAL
Intervention: Orbera IGB
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Spatz3 IGB
Number of subjects: 34
Study: 39674398

Group type: EXPERIMENTAL
Intervention: IMI/REL (500 mg/250 mg) every 6 h for 7-14 days
Number of subjects: 270

Group type: COMPARATOR
Intervention: PIP/TAZ (4000 mg/500 mg) every 6 h for 7-14 days
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: IMI/REL
Number of subjects: 270

Group type: COMPARATOR
Intervention: PIP/TAZ
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: IMI/REL and PIP/TAZ
Number of subjects: 270
Study: 39674524

Group type: EXPERIMENTAL
Intervention: Routine preprocedural PCI (reference group)
Number of subjects: 466

Group type: COMPARATOR
Intervention: No PCI (index group)
Number of subjects: 466
Study: 39674725

Group type: EXPERIMENTAL
Intervention: High animal protein diet (AP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: High vegetable protein diet (VP)
Number of subjects: 33
Study: 39675045

Group type: EXPERIMENTAL
Intervention: Live donor uterus transplantation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Preoperative investigations, live donor uterus transplantation, postoperative care, immunosuppression, IVF, follow-up, pregnancy care, delivery, graft removal
Number of subjects: 9
Study: 39675110

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Progressors
Number of subjects: 233

Group type: COMPARATOR
Intervention: Non-progressors
Number of subjects: 233
Study: 39675209

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine
Number of subjects: 10416

Group type: COMPARATOR
Intervention: Unvaccinated individuals
Number of subjects: 10416
Study: 39675376

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 731
Study: 39675486

Group type: EXPERIMENTAL
Intervention: Dapagliflozin plus metformin
Number of subjects: 2990

Group type: EXPERIMENTAL
Intervention: Dapagliflozin and metformin dual-therapy
Number of subjects: 2990

Group type: EXPERIMENTAL
Intervention: Dapagliflozin and metformin combination therapy
Number of subjects: 2990

Group type: COMPARATOR
Intervention: Total population
Number of subjects: 2990
Study: 39675563

Group type: EXPERIMENTAL
Intervention: Cold exposure
Number of subjects: 47
Study: 39675821

Group type: EXPERIMENTAL
Intervention: Comprehensive phenotypic evaluation including age, antibodies against glutamic acid decarboxylase, body mass index, glycated haemoglobin (HbA1c), indexes of insulin sensibility (HOMA2-IR) and secretion (HOMA2-beta)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Linkage with the population database for pragmatic follow-up
Number of subjects: 1200
Study: 39675824

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44